Bone marrow-derived mononuclear cells for ischemic stroke

This study aims to evaluate feasibility and tolerance of intravenous injection of autologous bone marrow-derived mononuclear cells (BM-MNCs) into patients who have recently (within 24-72 hours) experienced an acute ischemic stroke. Bone marrow cell harvest was feasible and safe to perform and there were no study-related severe adverse events. There was improvement in functional outcome.